Citigroup’s Teva Pharmaceuticals TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$85.6M Buy
2,527,031
+1,694,708
+204% +$56.4M 0.03% 526
2026
Q1
$25.1M Sell
832,323
-511,168
-38% -$16.4M 0.01% 953
2025
Q4
$41.9M Buy
1,343,491
+663,120
+97% +$16.3M 0.02% 701
2025
Q3
$13.7M Sell
680,371
-432,251
-39% -$7.59M 0.01% 1283
2025
Q2
$18.6M Sell
1,112,622
-2,956,644
-73% -$47.7M 0.01% 1006
2025
Q1
$62.5M Buy
4,069,266
+3,752,000
+1,183% +$67M 0.03% 491
2024
Q4
$6.99M Buy
317,266
+18,319
+6% +$333K ﹤0.01% 1653
2024
Q3
$5.39M Sell
298,947
-637,465
-68% -$11.2M ﹤0.01% 1781
2024
Q2
$15.2M Sell
936,412
-2,681,335
-74% -$41.3M 0.01% 1029
2024
Q1
$51M Buy
3,617,747
+3,247,067
+876% +$40.9M 0.03% 469
2023
Q4
$3.87M Sell
370,680
-35,804
-9% -$334K ﹤0.01% 1764
2023
Q3
$4.15M Sell
406,484
-328,347
-45% -$3.06M ﹤0.01% 1543
2023
Q2
$5.53M Sell
734,831
-4,060,549
-85% -$32.9M ﹤0.01% 1436
2023
Q1
$42.4M Buy
4,795,380
+4,043,784
+538% +$40M 0.03% 465
2022
Q4
$6.85M Sell
751,596
-458,241
-38% -$4M 0.01% 1320
2022
Q3
$9.76M Sell
1,209,837
-3,468,047
-74% -$30.7M 0.01% 1151
2022
Q2
$35.2M Buy
4,677,884
+4,398
+0.1% +$38.3K 0.03% 527
2022
Q1
$43.9M Sell
4,673,486
-1,032,819
-18% -$8.62M 0.03% 555
2021
Q4
$45.7M Buy
5,706,305
+3,620,439
+174% +$32.7M 0.02% 596
2021
Q3
$20.3M Sell
2,085,866
-1,866,840
-47% -$17.5M 0.01% 996
2021
Q2
$39.1M Buy
3,952,706
+1,527,717
+63% +$16.2M 0.02% 635
2021
Q1
$28M Sell
2,424,989
-688,300
-22% -$7.89M 0.02% 766
2020
Q4
$30M Sell
3,113,289
-6,203
-0.2% -$59.4K 0.02% 796
2020
Q3
$28.1M Sell
3,119,492
-96,690
-3% -$1.02M 0.02% 740
2020
Q2
$39.7M Buy
3,216,182
+217,097
+7% +$2.46M 0.03% 477
2020
Q1
$26.9M Buy
2,999,085
+103,238
+4% +$1.06M 0.02% 589
2019
Q4
$28.4M Buy
2,895,847
+164,963
+6% +$1.47M 0.02% 778
2019
Q3
$18.8M Sell
2,730,884
-714,437
-21% -$5.47M 0.01% 948
2019
Q2
$31.8M Sell
3,445,321
-666,134
-16% -$8.03M 0.03% 658
2019
Q1
$64.5M Buy
4,111,455
+2,071,417
+102% +$36.5M 0.06% 303
2018
Q4
$31.5M Sell
2,040,038
-2,951,725
-59% -$60.5M 0.03% 594
2018
Q3
$108M Sell
4,991,763
-576,844
-10% -$13.4M 0.1% 180
2018
Q2
$135M Buy
5,568,607
+3,987,104
+252% +$81.3M 0.12% 127
2018
Q1
$27M Sell
1,581,503
-547,112
-26% -$10.7M 0.02% 633
2017
Q4
$40.3M Buy
2,128,615
+207,530
+11% +$3.12M 0.03% 503
2017
Q3
$33.8M Buy
1,921,085
+736,602
+62% +$16.6M 0.03% 545
2017
Q2
$39.4M Sell
1,184,483
-348,057
-23% -$10.8M 0.04% 446
2017
Q1
$49.2M Buy
1,532,540
+661,269
+76% +$22.6M 0.04% 366
2016
Q4
$31.6M Sell
871,271
-162,829
-16% -$6.5M 0.03% 546
2016
Q3
$47.6M Buy
1,034,100
+848,209
+456% +$44.3M 0.04% 360
2016
Q2
$9.34M Sell
185,891
-38,723
-17% -$2.06M 0.01% 1081
2016
Q1
$12M Sell
224,614
-27,642
-11% -$1.62M 0.01% 877
2015
Q4
$16.6M Sell
252,256
-133,581
-35% -$8.26M 0.02% 832
2015
Q3
$21.8M Buy
385,837
+38,835
+11% +$2.52M 0.02% 680
2015
Q2
$20.5M Buy
347,002
+89,312
+35% +$5.51M 0.02% 768
2015
Q1
$16.1M Sell
257,690
-81,543
-24% -$4.74M 0.02% 898
2014
Q4
$19.5M Buy
339,233
+25,463
+8% +$1.42M 0.02% 825
2014
Q3
$16.9M Sell
313,770
-61,362
-16% -$3.25M 0.01% 912
2014
Q2
$19.7M Buy
375,132
+87,321
+30% +$4.46M 0.02% 811
2014
Q1
$15.2M Sell
287,811
-2,051,054
-88% -$94.8M 0.02% 887
2013
Q4
$93.7M Buy
2,338,865
+1,679,676
+255% +$66.1M 0.08% 206
2013
Q3
$24.9M Buy
659,189
+265,866
+68% +$10.4M 0.02% 626
2013
Q2
$15.4M Buy
+393,323
New +$15.3M 0.02% 800

Other funds holding TEVA

Citigroup's TEVA Position: Q2 2026 in Review

Citigroup increased its Teva Pharmaceuticals (TEVA) stake by 204% in Q2 2026, buying an estimated $56.4M and bringing the position to 2,527,031 shares worth $85.6M. The position accounts for 0.03% of the portfolio, ranked #526.

Citigroup first reported a position in TEVA in Q2 2013 and has held it in 53 quarters since. The position peaked at $135M in Q2 2018. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Citigroup held 2,527,031 shares of Teva Pharmaceuticals worth $85.6M as of Q2 2026.
  • Citigroup bought 1,694,708 Teva Pharmaceuticals shares in Q2 2026, an estimated $56.4M.
  • Teva Pharmaceuticals made up 0.03% of Citigroup's portfolio in Q2 2026, its #526 holding.
  • Citigroup first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Citigroup's Teva Pharmaceuticals position peaked at $135M in Q2 2018.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.